Optimización del sistema gastrorretentivo para la administración oral controlada de cinarizina mediante la metodología de superficie de respuesta

Autores/as

  • HN SHIVAKUMAR Department of Pharmaceutical Technology, K.L.E.S College of Pharmacy, Rajajinagar 2nd Block, Bangalore, India
  • BG DESAI Department of Pharmaceutical Technology, K.L.E.S College of Pharmacy, Rajajinagar 2nd Block, Bangalore, India
  • M PATEL Department of Pharmaceutical Technology, K.L.E.S College of Pharmacy, Rajajinagar 2nd Block, Bangalore, India

Palabras clave:

Cinarizina, Efervescente, Administración de fármaco flotante, Gastrorretentiva, Matriz hidrofílica

Resumen

Se propone un sistema fl otante efervescente de liberación controlada para la administración gastrorretentiva decinarizina. Para producir comprimidos de cinarizina fl otantes de liberación controlada mediante compresión directase utilizó un diseño de Box-Behnken 33. Se estudiaron los efectos de variables de formulación como los niveles deHPMC K4M (X1), bicarbonato sódico (X2) y ácido cítrico (X3) en las características de fl otabilidad del comprimidoy la liberación de fármaco. Los parámetros de respuesta como el tiempo de fl otabilidad total (TFT), la liberaciónal cabo de 10 h (Rel10), el tiempo necesario para la liberación del 50% del fármaco (t50) y el exponente de difusiónde Korsemeyer y Peppas (n), se analizaron mediante la metodología de superfi cie de respuesta. Los parámetros seanalizaron mediante el test F, y se generaron modelos matemáticos para cada parámetro de respuesta medianteanálisis de regresión lineal múltiple (MLRA) y análisis de varianza (ANOVA). Las tres variables de formulaciónestudiadas tuvieron un efecto signifi cativo (P < 0,05) en el TFT, mientras que los niveles de HPMC K4M y ácidocítrico infl uyeron signifi cativamente en la liberación de fármaco. Para desarrollar una formulación optimizada seutilizó la optimización numérica con enfoque de deseabilidad, estableciendo restricciones en las variables dependientese independientes. La formulación optimizada presentó una liberación de fármaco del 82,37 % durante el TFT de 8,5h en modo de orden cero un valor de t50 de 5,30 h. Los valores experimentales del TFT, t50 y Rel10 observados concordabancon los predichos por los modelos matemáticos, confi rmando la predictabilidad de MLRA y ANOVA.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 1993; 10: 143-195.

Baumgartner S, Tivadar A, Vrecer F, Kristl J. Development of floating tablets as a new approach to the treatment of

Helicobacter pylori infections. Acta Pharm 2001; 51: 21-33.

Klausner EA, Lavy E, Eyal S, Friedman M, Hoffmann A. Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. J Control Release 2003; 88: 117-126.

Matharu RS, Saghavi NM. Novel drug delivery system for captopril. Drug Dev Ind Pharm 1992; 18: 1567-1574.

Sawicki W. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. Int J Pharm 2002; 53: 29-35.

Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev Ind Pharm 1996; 22: 631-539.

Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst. 1998; 15: 243-283.

Deshpande AA, Shah NH, Rhodes CT, Malick AW. Development of a novel controlled-release system for gastric retention. Pharm Res 1997; 14: 815-819.

Li, S.; Lin, S.; Chein, Y.W.; Daggy, B.P.; Mirchandani, H.L. Statistical Optimisation of gastric floating system for oral controlled delivery of calcium. AAPS. Pharm. Sci. Tech. 2001, 2 (1), article 1, http://www.pharmscitech.com.

Li S, Lin S, Daggy BP, Mirchandani HL, Chein YW. Effect of HPMC and carbopol on the release and the floating properties of gastric floating drug delivery system using factorial design. Int J Pharm 2003; 253: 13-22.

Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M. Maincent P. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J Control Release 1999; 58: 195-205.

Davis SS, Stockwell AF, Taylor MJ, Hardy JG, Whalley DR, Wilson CG, Bechgaard H, Christensen FN. The effect of density on the gastric emptying of single and multiple-unit dosage forms. Pharm Res 1986; 3: 208-213.

Groning R and Heun G Dosage forms with controlled gastrointestinal passage-studies on the absorption of nitrofurantoin. Int J Pharm 1989; 56: 111-116.

Streubel A, Siepmann J, Brodmeier R. Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. Eur J Pharm Sci 2003; 18: 37-45.

Singh BN and Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000; 63: 235-259.

Sweetman SC. Antihistamines, In: Martindale, The Complete Drug Reference, 34rd Edn, Pharmaceutical Press, London, 2005; 419-443.

Ogata H, Aoyagi N, Kaniwa N, Ejima A, Sekine N, Kitamara M, Inoue Y. Gastric acidity dependent bioavailability of cinnarizine from two commercial capsules in human volunteers. Int J Pharm 1986; 29: 113-120.

Machida y, Inouye K, Tokumura T, Iwata M, Nagai T. Preparation and evaluation of intragastric buoyant preparations. Drug Design and Delivery. 1989; 4:155-161.

Goskonda SR, Hileman GA, Upadrashta SM. Controlled release pellets by extrusion spheronization. Int J Pharm 1994; 111: 89-97.

Lewis GA, Mathieu D, Phan Tan Lui R. Response Surface Methodogy In Pharmaceutical Experimental Design. New York, NY; Marcel Dekker, 1999; 185-246.

Indian Pharmacopoeia, 4th edition, The Controller of Publication, Ministry of Health and Family Welfare, 1996; 736.

Gunsel WC, Kanig KL, Tablets. In The Theory and Practice of Industrial Pharmacy, 2rd Ed.; Lachmann L, Liberman HA, Kanig, JL. Eds; Leas and Febiger: Phelidelphia, 1976; 321-358.

The USP 27-NF 22,United States Pharmacopoeial Convention, Rockville, MD., 2004; P 2621.

Baungartner S, Kristl J, Vrecer F, Vodopivec P, Zorko B. Optimization of floating matrix tablets and evaluation of their gastric residence time. Int J Pharm 2000; 195:125-135.

Korsemeyer R, Grunny R, Peppas N. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15: 25-35.

Higuchi T. Mechanisms of sustained action medications Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963;52:1145- 1149.

Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of tablets and capsules. J Pharm Sci 1969; 58: 1253-1257.

Narendra C, Srinath MS, Prakash Rao B. Development of three layered buccal compact containing metoprolol tartarate by statistical optimization technique. Int J Pharm. 2005; 304: 102-114.

Baumgartner S, Tivader A, Vrecer F, Kristl J. Development of floating tablets as a new approach to the treatment of Helicobacter pylori infections. Acta Pharm 2001; 51, 21-33.

Timmermans, J. Moes, A.J. How do floating dosage forms float? Int J Pharm 1990; 62: 207-216.

Dave BS, Amin AF, Patel MM. Gastroretentive drug delivery system of raitidine hydrochloride : Formulation and in vitro evaluation. 2004;5(2) article 34, http://www.pharmscitech.com.

Cedillo-Ramirez E, Villafuerte-Rhobles L. Effect of added pharmatose DCL11 on the sustained-release of metronidazole from methocel K4M and carbopol 971p NF floating matrices. Drug Dev Ind Pharm 2006; 32, 955-965.

Siepe S, Lueckel B, Kramer A, Ries A, Gurny R. Strategies for the design of hydrophilic matrix tablets with controlled microenvironmental pH. Int J Pharm 2006; 316: 14-20.

Takka S, Bharaj S, Sark A. Influence of methacrylic acid and hyroxypropylmethyl cellulose on the tablet properties and in vitro release of dextromethorphan hydrobromide. Pharmazie 2003; 58:886-890.

Xiaoqiang X, Minjie S, Feng Z, Yiqiao H. Floating matrix dosage form for phenoporalamine hydrochloride based on gas forming agent: In vito and in vivo evaluation in human volunteers. Int J Pharm 2006; 310:139-145.

El-Malah Y, Nazzal S. Hydrophilic matrices: Application of placket-burman screening design to model the effect of polyox-carbopol blends on drug release. Int J Pharm 2006; 309:163-170.

Singh B, Agarwal R. Design development and optimization of controlled release microcapsules of diltiazem hydrochloride. Ind J Pharm Sci 2002; 64 (2): 378-385.

Descargas

Publicado

2007-04-20

Cómo citar

1.
SHIVAKUMAR H, DESAI B, PATEL M. Optimización del sistema gastrorretentivo para la administración oral controlada de cinarizina mediante la metodología de superficie de respuesta. Ars Pharm [Internet]. 20 de abril de 2007 [citado 18 de abril de 2024];48(1):55-81. Disponible en: https://revistaseug.ugr.es/index.php/ars/article/view/4978

Número

Sección

Artículos Originales